Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results

Krystal Biotech (NASDAQ:KRYS) posted its quarterly earnings data on Monday. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07, Briefing.com reports. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the business earned ($0.67) EPS. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year.

Krystal Biotech Stock Up 2.1 %

KRYS opened at $174.41 on Wednesday. The company’s 50-day moving average price is $181.81 and its 200 day moving average price is $180.23. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of 98.54 and a beta of 0.82.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on KRYS shares. Stifel Nicolaus raised their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Chardan Capital raised their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. Citigroup upped their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech currently has a consensus rating of “Buy” and a consensus price target of $197.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).